ClinicalTrials.gg
RecruitingNCT07624500FAMUpdated Jul 1, 2026

Food and Metabolism Study

An interventional study of Avocado meal plan and Control meal plan in Prediabetes, Insulin Resistance and Triglycerides, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology. Recruiting at 1 site in United States. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

In this study, Investigators are interested in looking at the influence of eating avocados regularly, which are rich in healthy fats, fibers, and unique carbohydrates, on triglyceride and glucose metabolism in people with prediabetes and insulin resistance.

Read the detailed description

The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening. The research is designed as a randomized, 2-arm, parallel, diet-controlled, human clinical trial to investigate the effects of avocado consumption for 4 weeks on triglyceride metabolism in individuals with insulin resistance.

Participants will be asked to do the items described below. Visits will be held at the Clinical Nutrition Research Center (CNRC) on the Illinois Tech Campus, 10 W. 35th St., Suite 3D6-1 Chicago, IL, 60616.

SCREENING VISIT

Eligibility for the study is based on the above list (inclusion and exclusion criteria). Investigators will determine if participants qualify for the study at the Screening Visit by the following measurements:

  • General measurements: height, weight, body composition, waist circumference, blood pressure, vitals and body temperature
  • Fasting blood glucose (sugar) from a finger prick
  • Venous blood collection to assess blood glucose, insulin, and triglycerides
  • Pregnancy test, for women under the age of 60

Demographic questionnaire, health and medication questionnaire: participants will be asked to provide personal information, such as their name, date of birth, race, etc. Investigators will also ask them to answer questions about their demographics, health, medical history, and the medications they are taking. Based on the results of the blood draw, questionnaires, measurements, and evaluation of their health, they may meet the criteria and be invited to participate in the study.

PRE-STUDY / PRE-INTERVENTION VISIT (which may be performed on the same or a different day as the screening visit) The Pre-Study visit lasts \~45 minutes to 1 hour and participants will meet with one of our investigators who will provide detailed instructions on procedures of the study and "how to prepare for each of participants study days." They will be trained in all study procedures, including, but not limited to, foods to avoid during the study, medications/supplements to avoid, food diary recording, gastrointestinal diary recording and fasting overnight. Their study dates will be scheduled, and they will be provided with a study booklet, including a study calendar and all instructions covered at the Pre-Study Visit.

Medications/Supplements: If they are taking any medications or supplements that do not interfere with the study or have been OK'd by study staff, they will take those as instructed by their doctor and will record them in their diary. Investigators will train the participants on what foods or supplements are OK and NOT OK during the study at the Pre-Study Visit.

Self-Characteristics and Dietary Surveys: Participants will be asked to complete online surveys that cover usual gastrointestinal symptoms and a 24-hour food recall (https://asa24.nih.gov/).

STUDY DAY VISITS Study Visit 1 / Day 0 and Visit 5 / Day 28 Procedures

Staff collects study materials from the participant

1. Diary and provide 24 h recall (https://asa24.nih.gov/) Confirmation participant is ready to go for their study day by interview/discussion with the study staff

  1. Fasted overnight for 10-12 hours, including finger prick to verify usual fasting glucose
  2. Had a usual night of sleep (5-6 hours minimum)
  3. Avoided alcohol and vigorous physical activity 24 hours before the study day

After confirming they are ready for their study day, Investigators will proceed to an exam room to measure:

Anthropometrics: Investigators will measure weight, waist circumference and body composition.

Vital signs: Investigators will check their blood pressure, heart rate, and body temperature using standard clinic devices.

Once Investigators have collected measurements, they will proceed with an IV catheter to collect blood over multiple timepoints.

Blood collection: Participants will see the Licensed Health Care Provider (LHCP) for blood sample collection. Investigators will use an indwelling catheter (IV). This means Investigators will use a needle to put a thin tube in their arm or hand, from which Investigators can get blood samples while keeping them as comfortable as possible. This tube will stay in their arm until all blood drawings are completed during their visit. If there is difficulty with blood flow Investigators will ask the participant if they're comfortable with single stick blood collection, performed by LHCP using a butterfly needle. There will be nine blood draws in total over 5 hours.

Once the fasting blood draw is collected, Investigators will provide the participant with a breakfast in the form of a nutritionally complete liquid meal test (LMT).

Standard Liquid Meal Test (LMT): For this test, they will drink about 2 cups of vanilla flavored Ensure®. Ensure® is a nutritional supplement containing a mixture of sugars, fats, and protein and a variety of vitamins and minerals. The drink contains milk protein (suitable for lactose intolerance) and soy products. Investigators will ask if they are unwilling to consume any ingredients in the Ensure® drink. It may be unsafe for them to complete this test if they have an allergy to any of the components. The total amount participant will drink will be approximately 440 calories, 64g of Carbs, 12g of Fat, and 18g of Protein.

After all blood samples have been collected they will be provided with meals to last until V2 (\~ 1 week) and instructed how to fill out the dietary adherence log.

MEAL PICKUP VISITS Study Visit 2 / Day 7, Study Visit 3 / Day 14, Study Visit 4 / Day 21

Participants will not need to come fasted for meal pickup visits. Investigators will collect materials and ensure they are complying with the study protocols, and assess if there are any difficulties Investigators can help with. The following will be done at pickup visits:

Staff collects study materials from the participant 1. Diary and provide 24 h recall (https://asa24.nih.gov/) Staff collects weight and LDN does counseling as needed

1. Licensed Dietitian Nutritionist (LDN) will review compliance diary and weight changes and provide nutrition counseling as needed

02

Conditions studied

  • Prediabetes
  • Insulin Resistance
  • Triglycerides
  • Lipids Metabolism

Keywords

  • Triglycerides
  • Insulin resistance
  • Glucose metabolism
  • Lipids metabolism
03

In context

Prediabetic State

918 studies on the registry are indexed under Prediabetic State; 232 are open to participants now.

This study's planned enrollment of 82 is above the median of 62 across 762 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology is the lead sponsor of 61 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women, 40-70 years of age.
  • Fasting triglycerides (TG) >115 mg/dL.
  • Insulin resistance as measured by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) >2.5.
  • Able to provide .
  • Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study which will be almost all your food (\~ 80% of calories per day).
  • Able to come to the clinic up to 6 times during the study.
  • Able to maintain usual physical activity pattern.
  • Able to avoid/abstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit.

Exclusion criteria

Exclusion Criteria:

  • Men and women with known or suspected intolerance, allergies or to study foods or interventions.
  • Fasting blood sugar ≥125 mg/dL. Men and women with blood pressure >160 mmHg (systolic) / 100 mmHg (diastolic) at the screening visit.
  • Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year.
  • Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years.
  • Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints.
  • Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.). - - Men and women who consume nuts or peanuts daily or most days of the week.
  • Men and women who are not weight stable (+/-10lbs in previous 2 months). Men and women who have excessive use of drugs or alcohol (ie., addictions) within the past 2 years.
  • Men and women with documented physical or mental disease/condition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study.
  • Women who are lactating.
  • Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. Has used antibiotics within the previous 2 months.
  • History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
  • Excessive coffee and tea consumers (> 4 cups/d).
  • Donated blood within the last 3 months.
  • Women who are taking an unstable dose and brand of hormonal and/or a stable dose and brand for less than 6 months.
  • Unusual working hours (working overnight).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
82 participants (estimated)

Study arms

  • Active comparator
    Avocado meal plan

    2 meals and snack per day including one avocado in the meal, covering 80% of daily calories need.

    Other: Avocado meal plan

  • Placebo comparator
    Control meal plan

    2 meals and snacks per day without the inclusion of avocado, covering 80% of daily calories needs.

    Other: Control meal plan

Interventions

  • OtherAvocado meal plan

    American Diet with avocado

  • OtherControl meal plan

    American diet

06

What researchers measure

Primary outcomes

  1. Changes in serum biomarker: triglycerides

    analyzed by McLendon labs

    Time frame: baseline and 4 weeks

Secondary outcomes

  1. Changes in serum biomarker: insulin

    analyzed by McLendon labs

    Time frame: baseline and 4 weeks

  2. Changes in serum biomarker: glucose

    analyzed by McLendon labs

    Time frame: baseline and 4 weeks

  3. Changes in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Calculated from fasting glucose and insulin

    Time frame: baseline and 4 weeks

  4. Changes in Muscle Insulin Sensitivity Index (MISI)

    calculated using postprandial glucose and insulin concentrations measured by Randox clinical analyzer

    Time frame: baseline and 4 weeks

  5. Changes in total cholesterol

    fasting state, analyzed by Labcorp

    Time frame: baseline and 4 weeks

  6. Changes in Low-Density Lipoprotein (LDL) cholesterol

    fasting state, analyzed by Labcorp

    Time frame: baseline and 4 weeks

  7. Changes in High-Density Lipoprotein (HDL) cholesterol

    fasting state, analyzed by Labcorp

    Time frame: baseline and 4 weeks

  8. Changes in non-High-Density Lipoprotein (HDL) cholesterol

    fasting state, analyzed by Labcorp

    Time frame: baseline and 4 weeks

  9. Changes in Connecting Peptide (C-peptide)

    analyzed by McLendon labs

    Time frame: baseline and 4 weeks

  10. Changes in free fatty acids

    analyzed by Quest Diagnostics Lab

    Time frame: baseline and 4 weeks

  11. Changes in Glucagon-Like Peptide-1(GLP-1)

    analyzed by Luminex multi-target analyzer

    Time frame: baseline and 4 weeks

  12. Fructosamine

    analyzed by Randox clinical analyzer

    Time frame: baseline and 4 weeks

  13. Inflammation markers-Interleukin (IL)-6

    Analyzed by Luminex method

    Time frame: Baseline

  14. Inflammation markers-Interleukin (IL)-10

    Analyzed by Luminex method

    Time frame: Baseline

  15. Inflammation markers-Tumor necrosis factor alpha (TNF-α)

    Analyzed by Luminex method

    Time frame: Baseline

  16. Nuclear Magnetic Resonance (NMR) Lipoprotein Subfraction

    Analyzed by Labcorp

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Clinical Nutrition Research Center at IIT
    Chicago, Illinois 60616, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We would make all de-identified IPD collected during the trial (i.e., the study outcomes) publicly available upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: January 1, 2028-no end date

Access criteria: A steering committee composed of primary investigators from the study approves or denies research proposals.

Data sharing details ↗ · research.loveonetoday.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 46 industry-sponsored interventional studies with no phase under Prediabetic State, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 12 months is below that.

Counting every sponsor, half of 424 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Jun 28, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07624500
Collaborators
Hass Avocado Board
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 3, 2026
Primary completion
Jun 28, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Chelsea Preiss, MS
Contact
cpreiss@illinoistech.edu
312-567-5300
Indika Edirisinghe, PhD
Contact
iedirisi@illinoistech.edu
708-563-8178
Britt Burton-Freeman, PhD
principal investigator · Food Sci and Nut Programs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion